AN2 Therapeutics, Inc. Common Stock (ANTX) Stock Price
ANTXStock
$5.58+407.27%52W
Market Cap$210.57M
P/E—
PEG Ratio—
Div yield—
Beta-1.00
ANTX Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)424.61%
Price vs S&P 500 (4W)-1.54%
VGM Score84.22
ANTX Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.24 | -$0.18 | +25.00%(+$0.06) | |
| Q1 2026 | -$0.23 | -$0.29 | -26.09%(-$0.06) | |
| Q4 2025 | -$0.24 | -$0.29 | -20.83%(-$0.05) | |
| Q3 2025 | -$0.22 | -$0.31 | -40.91%(-$0.09) | |
| Q2 2025 | -$0.31 | -$0.21 | +32.26%(+$0.10) |
ANTX Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
2.17
4.29
4.29
4.38
Industry Peers — Pharmaceuticals(570)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ANTXAN2 Therapeutics, Inc. Common Stock | — | — | A | $5.58 |
| LLYEli Lilly & Co. | D | B | C | $1174.61 |
| JNJJohnson & Johnson | D | C | B | $268.04 |
| ABBVABBVIE INC. | D | C | B | $255.48 |
| MRKMerck & Co., Inc. | D | C | B | $148.35 |
| NVSNovartis AG | C | C | C | $153.81 |
| AZNAstraZeneca PLC | C | B | C | $162.70 |
| NVONovo-Nordisk A/S | B | C | C | $45.61 |
| ABTAbbott Laboratories | C | C | C | $112.47 |
| PFEPfizer Inc. | C | D | B | $27.96 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $541.69 |
About AN2 Therapeutics, Inc. Common Stock
AN2 Therapeutics develops small molecule therapeutics using proprietary boron chemistry, targeting infectious diseases and oncology with significant unmet medical needs. Its pipeline includes programs for Chagas disease, non-tuberculous mycobacterial infections, and melioidosis, with additional early-stage oncology initiatives.